CCO Treatment Updates
The Evolving Management of Drug-Drug Interactions in HIV Infection
Case Vignettes
Considering Drug-Drug Interactions When Selecting a First-line Antiretroviral Therapy for a Patient With a Complex Medical History
 
- Charles W. Flexner, MD
- Paul Pham, PharmD, BCPS
|
|
|
Charles W. Flexner, MD, and Paul Pham, PharmD, BCPS, coauthor a case vignette that describes the management of a patient with a medical history and multiple nonantiretroviral medications that increase the potential for drug-drug interactions.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe necessary dose adjustments when combining efavirenz and atazanavir/ritonavir
- Discuss the results of the ACTG 5142 study in regards to the use of NRTI-sparing regimen, lopinavir/ritonavir and efavirenz
- Summarize the pharmacokinetic differences of using once-daily vs twice-daily darunavir/ritonavir when combined with efavirenz
Abstract
|
Does Polypharmacy Increase the Likelihood of Renal Toxicity Among Persons With HIV?
- Lynda Szczech, MD, MSCE, FASN
|
|
|
In this CME-certified Case Vignette, Lynda Szczech, MD, MSCE, FASN, discusses the management of an HIV–infected patient with diabetic nephropathy and heart failure who is being treated with multiple medications in addition to antiretrovirals.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the frequency of acute kidney injury in patients taking a tenofovir-containing antiretroviral regimen
- Identify medications associated with increased risk of acute kidney injury
- List the factors that may contribute to the risk of renal toxicity in patients on antiretroviral therapy
Abstract
|
Management of a Patient Receiving an Initial Atazanavir/Ritonavir-Based Regimen With a Helicobacter Pylori Infection
- Ian McNicholl, PharmD, BCPS (AQ-Infectious Diseases), AAHIVE
|
|
|
Ian McNicholl, PharmD, BCPS, describes the pharmacologic considerations of treating a Helicobacter pylori infection in an HIV-infected patient with dyslipidemia receiving an initial atazanavir/ritonavir-based regimen.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe pharmacokinetic interactions between atazanavir and proton pump inhibitors
- Explain how combining PIs and pravastatin may affect pravastatin pharmacokinetics
- Cite expert recommendations for treating a Helicobacter pylori infection
Abstract
|
Interactive Tool
The HIV Drug-Drug Interactions Tool has now been superceded by the more comprehensive information available in CCO HIV inPractice. To review drug-drug interactions for ALL approved agents, as well as a wealth of other information, please visit http://www.inPractice.com, search for a drug, and review the results in the Drug Information section.
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|